Cancer Stem Cell News Volume 9.02 | Jan 22 2020

TOP STORY

Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis

Researchers demonstrated that Zika virus preferentially infected and killed glioblastoma stem cells and stem-like cells in medulloblastoma and ependymoma in a SOX2-dependent manner. [Cell Stem Cell] Abstract | Graphical Abstract

(Ranked by impact factor of the journal)

Synergistic Therapeutic Effect of Combined PDGFR and SGK1 Inhibition in Metastasis-Initiating Cells of Breast Cancer

Scientist found that PDGFR inhibition blocked AKT activation, whereas SGK1, which shared high-similarity kinase domain and overlapped substrates with AKT overexpression, remained active in metastasis-initiating cells. [Cell Death Differ] Abstract

Long Noncoding RNA FOXD2-AS1 Enhances Chemotherapeutic Resistance of Laryngeal Squamous Cell Carcinoma via STAT3 Activation

Investigators identified that long noncoding RNA FOXD2-AS1 regulated laryngeal squamous cell carcinoma therapeutic resistance by augmenting laryngeal squamous cell carcinoma stemness. [Cell Death Dis] Full Article

α-Mangostin Attenuates Stemness and Enhances Cisplatin-Induced Cell Death in Cervical Cancer Stem-Like Cells through Induction of Mitochondrial-Mediated Apoptosis

α-Mangostin significantly reduced the cell viability, sphere-forming ability, and expression of the cancer stem cell stemness markers of cancer stem cells-like cervical cancer cells. [J Cell Physiol] Abstract

ALDH1A3-mTOR Axis as a Therapeutic Target for Anticancer Drug-Tolerant Persister Cells in Gastric Cancer

The authors conducted a single cell analysis based on the stem cell- and gastric cell lineage-related gene expression in patient-derived gastric cancer cell models. [Cancer Sci] Abstract

GANT61 and Curcumin Loaded PLGA Nanoparticles for GLI-1 and PI3K/Akt Mediated Inhibition in Breast Adenocarcinoma

The nanoparticles induced cytotoxic effects to breast cancer cells at a mid-minimal dosage followed by cell death via autophagy and apoptosis, reduction in their target protein expression along with compromising the self-renewal property of cancer stem cells as revealed by their in vitro cell studies. [Nanotechnology] Abstract

Upregulated MicroRNA-194 Impairs Stemness of Cholangiocarcinoma Cells through the Rho Pathway via Inhibition of ECT2

The elevated expression of miR-194 or epithelial cell transforming sequence 2 (ECT2) silencing inhibited the Rho pathway, and further promoted the apoptosis and suppressed the stem cell proliferation, migration, and invasion of cholangiocarcinoma in vitro. [J Cell Biochem] Abstract

MTSS1 Suppresses Mammary Tumor-Initiating Cells by Enhancing RBCK1-Mediated p65 Ubiquitination

Scientists report a role of metastasis suppressor protein 1 (MTSS1) in suppressing tumor-initiating cells in breast cancer. MTSS1 suppressed tumorsphere formation in breast cancer cells. [Nat Cancer] Abstract

Chemosensitization of Prostate Cancer Stem Cells in Mice by Angiogenin and Plexin-B2 Inhibitors

Investigators showed that angiogenin and plexin-B2 regulated the stemness of prostate cancer stem cells, and that inhibitors of angiogenin/plexin-B2 sensitized prostate cancer stem cells to chemotherapy. [Commun Biol] Full Article

Subscribe to one of our other 19 science newsletters such as Neural Cell News & Hematopoiesis News.

Immunotherapy for Malignant Glioma: Current Status and Future Directions

Scientists introduce the diverse immunotherapeutic approaches available for treating glioma, highlighting the successes and challenges resulting from current clinical trials. [Trends Pharmacol Sci] Abstract

RNA N⁶-Methyladenosine Modification in Solid Tumors: New Therapeutic Frontiers

The authors discuss the functions of N⁶-methyladenosine mRNA machinery, including its writers that are components of the methyltransferase complex, its readers and its erasers in cancer. [Cancer Gene Ther] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Janssen Seeks Expanded Use of IMBRUVICA^® (Ibrutinib) in Combination with Rituximab for Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

The Janssen Pharmaceutical Companies announced the submission of a Type II variation application to the European Medicines Agency seeking to expand the label of IMBRUVICA^® to include ibrutinib in combination with rituximab for the first-line treatment of patients with chronic lymphocytic leukemia. [The Janssen Pharmaceutical Companies (Business Wire, Inc.)] Press Release

Novocure Announces National Reimbursement in Israel for Optune^® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Novocure announced that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients with newly diagnosed glioblastoma. [Novocure, Inc.] Press Release

Campus Attacks by Nationalists and Police Alarm India’s Scientific Community

The attack on one of India’s most prestigious universities sent shock waves around the country and is the latest sign that the political forces tearing apart Indian society are also affecting the country’s academic community. Students at JNU had been on strike for months against both a major hike in student fees and the government’s controversial Citizenship Amendment Act, widely decried as discriminatory against Muslims. [ScienceInsider] Editorial

Moffitt Cancer Center Details Links of Fired Scientists to Chinese Talent Programs

Six Florida cancer researchers who were dismissed last month for hiding their ties to a Chinese medical university appear to have been motivated by simple greed and a disregard for both institutional and federal rules. [ScienceInsider] Editorial

NEW 2^nd Immuno-Metabolic Mechanisms of Atherosclerosis Conference
March 1-4, 2020
Nassau, Bahamas

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Position – Stemness in Epigenetic Regulation (University of Freiburg)

NEW Postdoctoral Fellow – Research in Cancer Progression (The Wistar Institute)

NEW Postdoctoral Position – Bioinformatics and Leukemia Stem Cells (The Centre for Genomic Regulation)

Postdoctoral Fellow – Clonal Evolution of Cancer (Moffitt Cancer Center & Research Institute)

Team Leader – Clonal Evolution in Leukemia (Institute of Cancer Research)

Research Fellow – Glioblastoma Cell Signaling (University of Sussex)

Postdoctoral Associate – Leukemia and Brain Tumors (Ann and Robert H. Lurie Children’s Hospital of Chicago)

Postdoctoral Position – Glioma and Neurodevelopment (Mount Sinai)

Postdoctoral Scholarship – Brain Tumor Stemness (Lund University)

Research Associate – Cell Communication in Tumor Microenvironments (The University of Cambridge)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.